Fundamental Data for CYCC

CYCLACEL P(NSDQ:CYCC)

Xcyte Therapies, Inc. is a biotechnology company developing a new class of therapeutic products, which consist of activated, patient-specific T cells, known as Xcellerated T Cells, designed to enhance the body''s natural immune responses to treat cancer, infectious diseases and other medical conditions associated with weakened immune systems.

# Employees: 51

Address: ,,,

Phone:

Fax:

Website:

Email:

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

No Information

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 4/6/2010

Mean EPS (Next Qtr): ($0.17)

Mean EPS (Year): ($0.88)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 2

Shares Performance

Period	CYCC	Compare to S&P
YTD	90.48 %	57.64 %
4 Weeks	-12.76 %	-13.70 %
12 Weeks	-14.89 %	-19.76 %

Shares Information

Analyst Coverage: Y

Avg Volume: 177568

Shares Outstanding: 24M

Market Cap: $0.02B

52 Week High: $1.45

52 Week Low: $0.25

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 3/27/2006 CYCC split by factor of 0.100

Earnings Performance

EPS Growth in Last Quarter: 45.83 %

EPS Growth in Last Year: 56.67 %

Sales Growth in Last Quarter: -13.53 %

Sales Growth in Last Quarter: -14.50 %

Financials

Qtr Book Value: $2.46

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 20.050